Product Description
A Novel Selective Sphingosine-1-Phosphate-1 Receptor Modulator
Mechanisms of Action: S1P1 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Canada, Germany, Poland, Spain, United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 2: Dermatitis, Atopic
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2020-004767-77 | P2 |
Active, not recruiting |
Dermatitis, Atopic |
2023-01-22 |
|
IM018-010 | P1 |
Completed |
Healthy Volunteers |
2022-10-15 |
28% |
IM018-005 | P2 |
Completed |
Dermatitis, Atopic |
2022-08-22 |
|
IM018-004 | P1 |
Completed |
Healthy Volunteers |
2022-04-27 |
28% |
IM018-004 | P1 |
Completed |
Healthy Volunteers |
2022-04-27 |
28% |